Press Release: European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim

Author (Corporate)
Series Title
Series Details EMA/585784/2010 (23.9.10)
Publication Date 23/09/2010
Content Type

The European Medicines Agency (EMA), on 23 September 2010, recommended the suspension of the marketing authorisations for the rosiglitazone-containing anti-diabetes medicines Avandia, Avandamet and Avaglim. These medicines will stop being available in Europe within the next few months.
Source Link http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp
Related Links
EMA: Questions and answers on the suspension of rosiglitazone-containing medicines (Avandia, Avandamet and Avaglim) http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2010/09/WC500097003.pdf
EMA: Press Release: EMA/585784/2010 (23.9.10): European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf
Subject Categories
Countries / Regions